Heart failure is a consequence of various cardiovascular diseases and associated with poor
prognosis. Despite progress in the treatment of heart failure in the past decades, prevalence …

Inflammation has been recognized as a major pathophysiological contributor to the entire
spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with …

Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment
with sacubitril-valsartan reduces N-terminal pro–b-type natriuretic peptide (NT-proBNP) …

Heart failure (HF) has been singled out as an epidemic and is a staggering clinical and
public health problem, associated with significant mortality, morbidity, and healthcare …

Cardiovascular disease (CVD) causes significant mortality and remains the leading cause of
death globally. Thus, to reduce mortality, early diagnosis by measurement of cardiac …

Cardiac hypertrophy is an adaptive response to physiological and pathological overload. In
response to the overload, individual cardiac myocytes become mechanically stretched and …

Heart failure (HF) is a complex clinical syndrome characterized by the activation of at least
several neurohumoral pathways that have a common role in maintaining cardiac output and …

In heart failure (HF), acute decompensation can occur quickly and unexpectedly because of
worsening of chronic HF or to new‐onset HF diagnosed for the first time ('de novo'). Patients …

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a
human-relevant platform for cardiac function assessment. Alternative assays using hiPSC …

Heart failure (HF) is a multifactorial disorder and is usually the end stage of many
cardiovascular diseases (CVD). HF presents one of the highest morbidity and mortality …